Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-17T11:29:17.978Z Has data issue: false hasContentIssue false
  • English
  • Français

Metabolic Myopathies Discovered During Investigations of Statin Myopathy

Published online by Cambridge University Press:  02 December 2014

Steven K. Baker ,
Georgirene D. Vladutiu ,
Wendy L. Peltier ,
Paul J. Isackson  and
Mark A. Tarnopolsky
Steven K. Baker
Affiliation:
The Department of Medicine, McMaster University, McMaster University Medical Center, Hamilton, Ontario, Canada
Georgirene D. Vladutiu
Affiliation:
Departments of Pediatrics, Neurology, and Pathology, School of Medicine and Biomedical Sciences, State University of New York, Buffalo, Buffalo, New York
Wendy L. Peltier
Affiliation:
Department of Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Paul J. Isackson
Affiliation:
Departments of Pediatrics, Neurology, and Pathology, School of Medicine and Biomedical Sciences, State University of New York, Buffalo, Buffalo, New York
Mark A. Tarnopolsky
Affiliation:
Department of Pediatrics, Neuromuscular Disease Clinic, McMaster University, McMaster University Medical Center, Hamilton, Ontario, Canada
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The statins have emerged as the dominant class of drug for the treatment of hypercholesterolemia. These medications are generally well tolerated. However, myalgias, the most frequent side-effect, occur in up to 7% of patients. Transaminitis and skeletal myotoxicity, with elevated serum creatine kinase (CK) levels (i.e., >10 times the upper limit of normal), occur with reported frequencies of 1% and 0.1%, respectively. Various hypotheses have been proposed to explain the relationship between statin therapy and the spectrum of muscle dysfunction manifested by myalgia, myopathy, and rhabdomyolysis.

Statin-mediatd inhibition of mevalonate metabolism impairs the synthesis of isoprenylated products–the most notable of which is ubiquinone. However, isoprenylation is responsible for the post-translational modification of up to 2% of cellular proteins. Therefore, numerous metabolic pathways are potentially modified by statin-mediated hypoprenylation. Subclinical defects in one or more energy-deriving pathways may be unmasked upon exposure to the pleotropic effects of statins. Such pharmacogenomic synergism may underlie the development of “statin myopathy” in a subset of patients. In this regard, we describe four patients with mutations in the myophosphorylase (PYGM; MIM 232600), myoadenylate deaminase (AMPD1; MIM 102770), and carnitine palmitoyltransferase (CPT2; MIM 600650) genes whose diagnoses became apparent during the course of investigations for statin-induced myalgias and hyperCKemia.

Type
Peer Reviewed Letter
Information
Canadian Journal of Neurological Sciences , Volume 35 , Issue 1 , March 2008 , pp. 94 - 97
Copyright
Copyright © The Canadian Journal of Neurological 2008

References

1. Ucar, M, Mjorndal, T, Dahlqvist, R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000; 22: 441–57.CrossRefGoogle ScholarPubMed
2. Maron, DJ, Fazio, S, Linton, MF. Current perspectives on statins. Circulation. 2000; 101: 207–13.Google Scholar
3. Epstein, WW, Lever, D, Leining, LM, Bruenger, E, Rilling, HC. Quantitation of prenylcysteines by a selective cleavage reaction. Proc Natl Acad Sci U S A. 1991; 88: 9668–70.Google Scholar
4. Vladutiu, GD, Simmons, Z, Isackson, PJ, Tarnopolsky, M, Peltier, WL, Barboi, AC, et al. Genetic risk factors associated with lipid lowering drug-induced myopathies. Muscle Nerve. 2006; 34: 153–62.Google Scholar
5. Frudakis, TN, Thomas, MJ, Ginjupalli, SN, Handelin, B, Gabriel, R, Gomez, HJ. CYP2D6*4 polymorphism is associated with statininduced muscle effects. Pharmacogenet Genomics. 2007; 17: 695–707.Google Scholar
6. Takeda, M, Noshiro, R, Onozato, ML, Tojo, A, Hasannejad, H, Huang, XL, et al. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur J Pharmacol. 2004; 483: 133–8.Google Scholar
7. Oh, J, Ban, MR, Miskie, BA, Pollex, RL, Hegele, RA. Genetic determinants of statin intolerance. Lipids Health Dis. 2007; 6: 7.CrossRefGoogle ScholarPubMed
8. Ruano, G, Thompson, PD, Windemuth, A, Seip, RL, Dande, A, Sorokin, A, et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve. 2007; 36: 329–35.CrossRefGoogle ScholarPubMed
9. Sirvent, P, Mercier, J, Vassort, G, Lacampagne, A. Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun. 2005; 329: 1067–75.Google Scholar
10. Kang, L, Fang, Q, Hu, SJ. Regulation of phospholamban and sarcoplasmic reticulum Ca2+-ATPase by atorvastatin: implication for cardiac hypertrophy. Arch Pharm Res. 2007; 30: 596–602.CrossRefGoogle ScholarPubMed
11. Velho, JA, Okanobo, H, Degasperi, GR, Matsumoto, MY, Alberici, LC, Cosso, RG, et al. Statins induce calcium-dependent mitochondrial permeability transition. Toxicology. 2006; 219: 124–32.Google Scholar
12. Matzno, S, Yasuda, S, Juman, S, Yamamoto, Y, Nagareya-Ishida, N, Tazuya-Murayama, K, et al. Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. J Pharm Pharmacol. 2005; 57: 1475–84.Google Scholar
13. Sakamoto, K, Honda, T, Yokoya, S, Waguri, S, Kimura, J. Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers. FASEB J. 2007; 21(14):4087–94.Google Scholar
14. Baker, SK, Tarnopolsky, MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med. 2001; 24: 258–72.Google ScholarPubMed
15. Chariot, P, Abadia, R, Agnus, D, Danan, C, Charpentier, C, Gherardi, RK. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med. 1993; 94: 109–10.Google Scholar
16. Thomas, JE, Lee, N, Thompson, PD. Statins provoking MELAS Syndrome. A case report. Eur Neurol. 2007; 57: 232–5.Google Scholar
17. Goli, AK, Goli, SA, Byrd, RP Jr., Roy, TM. Simvastatin-induced lactic acidosis: a rare adverse reaction? Clin Pharmacol Ther. 2002; 72: 461–4.CrossRefGoogle ScholarPubMed
18. Perez-Calvo, J, Civeira-Murillo, F, Cabello, A. Worsening myopathy associated with ezetimibe in a patient with McArdle disease. Qjm. 2005; 98: 461–2.Google Scholar
19. Garcia-Calvo, M, Lisnock, J, Bull, HG, Hawes, BE, Burnett, DA, Braun, MP, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005; 102: 8132–7.Google Scholar
20. Walravens, PA, Greene, C, Frerman, FE. Lovastatin, isoprenes, and myopathy. Lancet. 1989; 2: 1097–8.Google Scholar
21. Haller, RG. Treatment of McArdle disease. Arch Neurol. 2000; 57: 923–4.Google Scholar
22. Tsao, CY, Mendell, JR. Combined partial deficiencies of carnitine palmitoyltransferase II and mitochondrial complex I presenting as increased serum creatine kinase level. J Child Neurol. 2002; 17: 304–6.Google Scholar
23. Lam, CW, Lau, CH, Williams, JC, Chan, YW, Wong, LJ. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr. 1997; 156: 562–4.CrossRefGoogle ScholarPubMed
24. Delgado-Lopez, F, Bautista-Lorite, J, Villamil-Fernandez, F. Worsening for using statin in carnitine palmityol transferase deficiency myopathy. Rev Neurol. 2004; 38: 1095.Google Scholar
25. Arduini, A, Peschechera, A, Giannessi, F, Carminati, P. Improvement of statin-associated myotoxicity by L-carnitine. J Thromb Haemost. 2004; 2: 2270–1.Google Scholar
26. Bhuiyan, J, Seccombe, DW. The effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibition on tissue levels of carnitine and carnitine acyltransferase activity in the rabbit. Lipids. 1996; 31: 867–70.Google Scholar
27. Kaufmann, P, Torok, M, Zahno, A, Waldhauser, KM, Brecht, K, Krahenbuhl, S. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci. 2006; 63(19-20):2415–25.Google Scholar
28. Yano, M, Matsumura, T, Senokuchi, T, Ishii, N, Murata, Y, Taketa, K, et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res. 2007; 100: 1442–51.Google Scholar
29. Scatena, R, Bottoni, P, Martorana, GE, Vincenzoni, F, Botta, G, Pastore, P, et al. Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology. Eur J Pharmacol. 2007; 567: 50–8.Google Scholar
30. Phillips, PS, Haas, RH, Bannykh, S, Hathaway, S, Gray, NL, Kimura, BJ, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002; 137: 581–5.CrossRefGoogle ScholarPubMed
31. Krivosic-Horber, R, Depret, T, Wagner, JM, Maurage, CA. Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. Eur J Anaesthesiol. 2004; 21: 572–4.Google Scholar
32. Guis, S, Bendahan, D, Kozak-Ribbens, G, Figarella-Branger, D, Mattei, JP, Pellissier, JF, et al. Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility. Arthritis Rheum. 2003; 49: 237–8.Google Scholar
33. Livingstone, C, Al Riyami, S, Wilkins, P, Ferns, GA. McArdle’s disease diagnosed following statin-induced myositis. Ann Clin Biochem. 2004; 41: 338–40.Google Scholar
34. Tsivgoulis, G, Spengos, K, Karandreas, N, Panas, M, Kladi, A, Manta, P. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med. 2006; 166: 1519–24.Google Scholar
35. Voermans, NC, Lammens, M, Wevers, RA, Hermus, AR, van Engelen, BG. Statin-disclosed acid maltase deficiency. J Intern Med. 2005; 258: 196–7.Google Scholar
36. Takagi, A, Shiio, Y. Pravastatin-associated polymyositis, a case report. Rinsho Shinkeigaku. 2004; 44: 25–7.Google Scholar
37. Riesco-Eizaguirre, G, Arpa-Gutierrez, FJ, Gutierrez, M, Toribio, E. Severe polymyositis with simvastatin use. Rev Neurol. 2003; 37: 934–6.Google Scholar
38. Noel, B, Cerottini, JP, Panizzon, RG. Atorvastatin-induced dermatomyositis. Am J Med. 2001; 110: 670–1.Google Scholar
39. Vasconcelos, OM, Campbell, WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve. 2004; 30: 803–7.CrossRefGoogle ScholarPubMed
40. Parmar, B, Francis, PJ, Ragge, NK. Statins, fibrates, and ocular myasthenia. Lancet. 2002; 360: 717.Google Scholar
41. Baker, SK, Tarnopolsky, MA. Sporadic rippling muscle disease unmasked by simvastatin. Muscle Nerve. 2006; 34: 478–81.Google Scholar